Study title: Post-marketing surveillance study of Seractil 200 mg and 300 mg film-coated tablets involving 1400 patients with rheumatic diseases. Phelps W. et al.. (Nov 1994): Final report Gebro; English translation, original report (in German language).Post-marketing surveillance study of Seractil 200 mg and 300 mg film-coated tablets involving 1400 patients with rheumatic diseases. Phelps W. et al.. (Nov 1994): Final report Gebro; English translation, original report (in German language).
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Anesthesia and Analgesia [E03] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: DEXAMETHASONE AND NEOMYCIN | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |